Remove thanks
article thumbnail

New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)

Xconomy

Four years after approval the two PCSK9 blockers on the market have yet to crack $1 billion in annual sales, combined, thanks to a gloves-off effort by insurers to beat back their use. Results from a big study are due Sept. One of the two drugs might even be on life support. Now a third PCSK9 inhibitor is in the ring.

Study 102
article thumbnail

With New Data, Drug Combos, Lung Cancer Experts Scramble to Keep Pace

Xconomy

Thanks in large part to the arrival of cancer immunotherapy, things are much different today. In one study , 16 percent of 129 patients receiving an. When oncologist Renato Martins finished his medical training, advanced lung cancer was almost certainly a quick death sentence. “I Here’s a recent example.

Study 79
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

SCE Carrier Solutions – Advancing to Meet the Growing Bandwidth Needs of our Customers

Southern California Edison Blog

In addition to our 24/7 Network Operations Center (NOC) support, you will have easy access to a variety of other helpful resources including our new blog, white papers, case studies and product specifications. Since 1994, we have had a lot of success as a wholesale carrier selling network capacity to other service providers.

article thumbnail

This Week in Venture Capital – Episode 3

Both Sides of the Table

Thank you to anybody who sent Jason a note on Twitter on my behalf. Finally, a lot of people asking me about typos on my blog. Studying for the SAT, LSAT, GMAT, TOEFL, MCAT and other standardized tests in the US is a massive market that has been dominated for years by Kaplan and Princeton Review. OK, it’s official!

article thumbnail

Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More

Xconomy

—Alnylam Pharmaceuticals (NASDAQ: ALNY ) of Cambridge, MA, said that it would shelve its drug revusiran after 18 patients died in a Phase 3 study to treat the rare disease transthyretin amyloidosis. She refused to discuss Edison at the time. Officials declined to say how many of the 18 were taking the drug and how many were on placebo.

article thumbnail

My Chat with Dan Primack of PEHub

Both Sides of the Table

That’s thanks to Dan Primack , founding editor. But this gets all the space on prominent blogs because it’s what bloggers like to cover.&# It’s self selecting. A recent study said seed stage valuations have been quite static recently. This created a big gap for people to come in.

article thumbnail

Future of The Cloud is Bright | Just Ask the Market

Tech Zulu Event

Hulme, blogging at Cloud Commons , believes that the cloud will spur a jobs explosion, though the jobs descriptions will differ. An IDC study commissioned on behalf of Microsoft has shown that cloud computing will be responsible for creating nearly 14 million new jobs between 2011 and 2015.